A Multi-Center Phase I Trial of Neratinib and Fam-Trastuzumab Deruxtecan in Patients With Advanced Refractory Gastric Cancer

Namrata Vijayvergia

doi:10.6004/jnccn.2024.0016

A Multi-Center Phase I Trial of Neratinib and Fam-Trastuzumab Deruxtecan in Patients With Advanced Refractory Gastric Cancer

Research output: Contribution to journal › Editorial

Original language	English
Number of pages	2
Journal	Journal of the National Comprehensive Cancer Network
Volume	22
Issue number	2
DOIs	https://doi.org/10.6004/jnccn.2024.0016
State	Published - Mar 2024

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.6004/jnccn.2024.0016

Cite this

@article{113bca5534e84a7da3b32063bfd0eab0,

title = "A Multi-Center Phase I Trial of Neratinib and Fam-Trastuzumab Deruxtecan in Patients With Advanced Refractory Gastric Cancer",

author = "Namrata Vijayvergia",

year = "2024",

month = mar,

doi = "10.6004/jnccn.2024.0016",

language = "English",

volume = "22",

journal = "Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

publisher = "Cold Spring Publishing LLC",

number = "2",

}

TY - JOUR

T1 - A Multi-Center Phase I Trial of Neratinib and Fam-Trastuzumab Deruxtecan in Patients With Advanced Refractory Gastric Cancer

AU - Vijayvergia, Namrata

PY - 2024/3

Y1 - 2024/3

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=purepublist2023&SrcAuth=WosAPI&KeyUT=WOS:001278453000001&DestLinkType=FullRecord&DestApp=WOS_CPL

U2 - 10.6004/jnccn.2024.0016

DO - 10.6004/jnccn.2024.0016

M3 - Editorial

SN - 1540-1405

VL - 22

JO - Journal of the National Comprehensive Cancer Network

JF - Journal of the National Comprehensive Cancer Network

IS - 2

ER -

A Multi-Center Phase I Trial of Neratinib and Fam-Trastuzumab Deruxtecan in Patients With Advanced Refractory Gastric Cancer

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this